HDAC inhibitor

March 26, 2019

Trials to Test Abexinostat in Heavily Treated DLBCL, Follicular Lymphoma

News

Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma (DLBCL) ... Read more

June 5, 2018

Phase 2 Data Continues to Support Remetinostat in Easing Itching in Early Stage Mycosis Fungoides

News

Topical remetinostat gel significantly reduces itching in patients with a kind of cutaneous T-cell lymphoma called mycosis fungoides, data from a Phase 2 trial shows. The medicine also reduced the ... Read more

October 12, 2017

Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants

News

A Phase 2 trial is currently enrolling participants to evaluate 4SC‘s investigational therapy resminostat as a maintenance therapy for advanced-stage cutaneous T-cell lymphoma (CTCL). The RESMAIN study (NCT02953301) is being conducted at about ... Read more

February 14, 2017

New Oral Drug Shows Promise in Halting Growth of B-Cell Lymphoma Tumors

News

By simultaneously inhibiting two proteins that cancer cells need to survive, researchers offer a potentially promising therapeutic approach to treat B-cell lymphomas, according to a new study. CUDC-907, a new oral ... Read more